Findings

What do systematic reviews say?

117 questions · 119 findings · 20 reviews · Breast Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 11 · 9.2%GRADE not reported 0 · 0%Very low 49 · 41.2%Low 42 · 35.3%Moderate 11 · 9.2%High 6 · 5%

Summary of findings table ‐ Systemic therapy vs control

Safety of systemic therapies for the treatment of AIMSS · health problem or population

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 1250 participants
Very low

Summary of findings table ‐ Systemic therapy vs control

Change in grip strength · women with early breast cancer

Summary of findings table ‐ Systemic therapy showed no clear difference in change in grip strength from baseline to end of intervention compared with control (low certainty).

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
RR 1.08 [0.37, 3.17]
1 study · 137 participants
Low

Summary of findings table ‐ Systemic therapy vs control

Safety of systemic therapies for the treatment of AIMSS · women with early breast cancer

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 344 participants
Very low

Summary of findings table ‐ Systemic therapy vs control

Effect on discontinuation of aromatase inhibitors (AI) · women with early breast cancer

Summary of findings table ‐ Systemic therapy showed no clear difference in effect on discontinuation of aromatase inhibitors (AI) compared with control (low certainty).

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
RR 0.16 [0.01, 2.99]
1 study · 147 participants
Low

Summary of findings table ‐ Systemic therapy vs control

Effect on breast cancer‐specific quality of life (BCS‐QoL) · women with early breast cancer

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 44 participants
Low

Summary of findings table ‐ Systemic therapy vs control

Health‐related quality of life (HRQoL) · women with early breast cancer

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1 participants
Low

Summary of findings table ‐ Systemic therapy vs control

Incidence of AIMSS · women with early breast cancer

It is very uncertain whether summary of findings table ‐ Systemic therapy changes incidence of AIMSS compared with control (very low certainty).

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
RR 0.82 [0.63, 1.06]
2 studies · 240 participants
Very low

Summary of findings table ‐ Systemic therapy vs control

Change in pain from baseline to end of intervention · health problem or population

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 1099 participants
Very low

Summary of findings table ‐ Systemic therapy vs control

Change in stiffness from baseline to end of intervention · health problem or population

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 295 participants
Very low

Intervention not reported

Breast cancer mortality ‐ tamoxifen · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)

1 finding from 1 review

Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 97 participants
Low

Intervention not reported

Recurrence ‐ tamoxifen · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)

1 finding from 1 review

Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1956 participants
Very low

Intervention not reported

Recurrence ‐ AIs · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)

1 finding from 1 review

Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 175 participants
Very low

Intervention not reported

Recurrence (loco‐regional) ‐ endocrine therapies not separated (exemestane (AI)/tamoxifen (SERM)) · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)

1 finding from 1 review

Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 284 participants
Very low

Intervention not reported

Recurrence (distance) ‐ endocrine therapies not separated (exemestane (AI)/tamoxifen (SERM)) · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)

1 finding from 1 review

Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 284 participants
Very low

Intervention not reported

Incidence of a secondary primary breast cancer (e.g. in the contralateral breast) ‐ endocrine therapies not separated (exemestane (AI)/tamoxifen (SERM)/unknown) · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)

1 finding from 1 review

Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 87 participants
Very low

Intervention not reported

Incidence of invasive breast cancer and DCIS ‐ tamoxifen · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)

1 finding from 1 review

Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 51 participants
Low

Exercise vs usual care

Overall change in worst pain scores · women with aromatase inhibitor‐induced musculoskeletal symptoms (AIMSS)

1 finding from 1 review

Exercise therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2020 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 284 participants
Very low

Exercise vs usual care

Stiffness · women with aromatase inhibitor‐induced musculoskeletal symptoms (AIMSS)

1 finding from 1 review

Exercise therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 53 participants
Low

Exercise vs usual care

Change in grip strength · women with aromatase inhibitor‐induced musculoskeletal symptoms (AIMSS)

1 finding from 1 review

Exercise therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 83 participants
Very low

Exercise vs usual care

Overall change in health‐related quality of life · women with aromatase inhibitor‐induced musculoskeletal symptoms (AIMSS)

1 finding from 1 review

Exercise therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 123 participants
Very low